title: Recent innovations in mRNA vaccines.
abstract: Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been shown to be safe and immunogenic, although none have yet been licensed for human use. Recently, mRNA based vaccines have emerged as an alternative approach. They promise the flexibility of plasmid DNA vaccines, without the need for electroporation, but with enhanced immunogenicity and safety. In addition, they avoid the limitations of anti-vector immunity seen with viral vectors, and can be dosed repeatedly. This review highlights the key papers published over the past few years and summarizes prospects for the near future.
authors.affiliation: GSK Vaccines, 350 Massachusetts Avenue, Cambridge, MA 02139, United States.
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Ulmer
authors.affiliation: Avidity NanoMedicines, 10975 North Torrey Pines Road, La Jolla, CA 92037, United States. Electronic address: andy@aviditynano.com.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Geall
mesh_terms: D000818:Animals; D006801:Humans; D012333:RNA, Messenger / Q000235:genetics*; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology*
chemical_list: D012333:RNA, Messenger; D019444:Vaccines, DNA